▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2596 by analyst upside · 2026-06-27
RCUS
Arcus Biosciences, Inc.
Healthcare · Market Cap $4B · P/E 0x
ANALYST PRICE TARGET
+15.3%
implied upside to consensus target
Current Price $31.0
Consensus Target $35.75
Bull Target $47.0
Bear Target $22.0
Analysts Covering 12
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
9
Hold
3
Sell
0
52-Week Low $7.91
52-Week High $31.44
YTD Return +33.1%
FUNDAMENTALS
Market Cap $4B
P/E Ratio (TTM) N/A
Forward P/E -10.0x
EPS (TTM) $-3.17
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $236M
Profit Margin -156.4%
52-WEEK RANGE
52-Week Low $7.91
52-Week High $31.44
Current Price $31.0
Bear Target $22.0
Bull Target $47.0
● Now $31.0 ● Target $35.75
TRADING DATA
Avg Volume 1.2M
YTD Return +33.1%
Analyst Count 12
Consensus Buy
Upside to Target +15.3%
Last Updated 2026-06-27

ANALYST SUMMARY

Arcus Biosciences, Inc. (RCUS) is currently trading at $31.0 with a Wall Street consensus price target of $35.75, implying potential upside of 15.3% over the next 12 months. 12 analysts currently cover RCUS, with a consensus rating of Buy - 75% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $47.0, while the most cautious has a target of $22.0.

RCUS operates in the Healthcare sector with a market capitalisation of $4B. The stock is up 33.1% year-to-date and is currently trading near the upper end of its 52-week range of $7.91 – $31.44.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

ACAD +25.0%
ACADIA Pharmaceuticals Inc.
$4B · P/E 11.5x · Buy
DOCS +21.7%
Doximity, Inc.
$4B · P/E 20.3x · Buy
CON +4.4%
Concentra Group Holdings Parent, Inc.
$4B · P/E 21.7x · Buy
CPRX +0.5%
Catalyst Pharmaceuticals, Inc.
$4B · P/E 18.2x · Buy
OPCH +31.0%
Option Care Health, Inc.
$3B · P/E 16.8x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for RCUS, with each firm's 90-day track record across all stocks we track. See full firm rankings →

LifeSci Capital ● Initiated
Outperform 2026-06-04 Building track record
Morgan Stanley — Reiterated
Equal-Weight → Equal-Weight 2026-05-11 Building track record
Goldman Sachs — Reiterated
Buy → Buy 2026-05-07 Building track record
Wedbush — Reiterated
Outperform → Outperform 2026-04-02 Building track record
Citigroup — Reiterated
Buy → Buy 2026-03-05 Building track record
Leerink Partners — Reiterated
Outperform → Outperform 2026-03-02 29% win rate (7 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-03-02 31% win rate (48 calls)
Wells Fargo ↓ Downgrade
Overweight → Equal-Weight 2026-02-12 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
48
out of 100
Coverage depth
20/30
Consensus clarity
14/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →